Marco Meglio

Brian Wainger, MD, PhD, assistant professor of neurology and anesthesiology, Harvard Medical School, discussed the recently published phase 2 trial a repurposed epilepsy drug in patients with ALS.

No significant between-group differences were detected in symptomatic intracerebral hemorrhage or 90-day mortality.

After winning FDA approval in October 2020, the new expanded indication includes adolescents aged 12 and older with episodic or chronic migraine.

The asymmetry of mediotemporal atrophy and a lesser impact of APOE4 and TDP-43 on the integrity of memory circuitry may have constituted preservation in primary progressive aphasia.

If approved, INP104 would be the first and only delivery system to explore the vascular-rich upper nasal space as a therapeutically viable treatment pathway.

Any intracerebral hemorrhage was observed less frequently in the mechanical thrombectomy alone group than in the combined group.

The average number of inpatient claims per year was higher for patients with SMA than their matched non-SMA patients, with respiratory illness the most common reason for an inpatient admission among all patients with SMA.

Hippocampal-sparing and limbic-predominant atrophy were also associated with incident dementia, with faster cognitive decline in the limbic predominant atrophy group.

The Evelyn F. McKnight Neurocognitive Scholar at the University of Miami Miller School of Medicine detailed his study on the correlations between sleep and cognitive decline in middle-aged Hispanics.

The calculation of fVPA based on this equation resulted in a misinterpretation in 40% of measurements with around 75% of them overestimating the actual measured fVPA.

Having a blood test available could help eliminate wait time in the emergency room and could reduce the number of unnecessary CT scans by up to 40%, according to Abbott, the test’s developer.

People who were genetically predisposed to smoking behaviors were at a 63% greater risk for subarachnoid hemorrhage.

The findings showed that 64% of EEG education programs did not utilize objective measures to assess EEG milestones.

The ability of the ABC/2 method to correctly identify patients with an infarct volume below a pre-defined cut-point proved to be very high for various cut-points.

The assistant professor of neurology and anesthesiology at Harvard Medical School discussed the landscape of ALS treatments and his outlook on how the future might evolve.

The findings suggest and confirm previous studies that suggested plasma p-tau181 may be used as a measure to monitor Alzheimer disease progression in clinical practice and treatment trials.

The Pfizer candidate PF-06939926 has also received fast track, orphan drug, and rare pediatric disease designations from the FDA.

The clinical fellow at Massachusetts General Hospital detailed his research on neurology resident EEG education, and the increased need for more consistency throughout programs.

The hATTR amyloidosis treatment demonstrated an encouraging safety and tolerability profile, with a new drug application submission expected to come this year.

The phase 4 study will use total score on the Hammersmith Infant Neurological Examination Section 2 motor milestones as the primary end point over a 2-year period.

The percentage of women who had ≥1 change in an antiepileptic drug dose or an overall dose increase during pregnancy and a decrease in dose during the postpartum period was higher among pregnant women than controls.

Although the percentage of total seizures arising from REM was low, it is notable that 2 out of 26 patients (7.7%) had REM-onset seizures.

The Expanded Access Program will offer treatment for patients with ALS who have completed the phase 3 clinical trial and will not interfere with data or regulatory timelines.

Individuals whose mothers had pregestational diabetes mellitus had a statistically significant 2.3-fold increased risk of developing multiple sclerosis.

Raymond Sanchez, MD, chief medical officer of Cerevel Therapeutics, discussed tavapadon, a drug intended to treat Parkinson disease that is currently being tested in a slew of clinical trials.

Neuronaute consists of a smart shirt and smart cap containing biosensors that monitor physiological characteristics, such as muscle activity and heart and respiratory rate.

Objective reduction in tremor was accompanied by improvement in specific motor tasks and a larger proportion of patients in the botulinum neurotoxin group reporting a global subjective improvement in symptoms.

In addition to the device showing a safe profile, it helped patients with pain relief from their migraine and increased functional ability.

The agent will aim to be the first and only FDA-approved liquid formulation of topiramate, with a PDUFA date set in Q3 of 2021.

Jennifer Robblee, MD, neurologist, Barrow Neurological Institute, shares her takeaways about how migraine care shifted this year and how it may continue to shift going forward.